var data={"title":"Alglucosidase alfa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alglucosidase alfa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/224754?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alglucosidase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alglucosidase alfa: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=alglucosidase-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alglucosidase alfa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708603\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <b>Lumizyme:</b> Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions. Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment. Closely observe patients during and after alglucosidase alfa administration and be prepared to manage anaphylaxis and hypersensitivity reactions. Inform patients of the signs and symptoms of anaphylaxis, hypersensitivity reactions, and immune-mediated reactions, and have them seek immediate medical care if signs and symptoms occur.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <b>Myozyme:</b> Life-threatening anaphylactic, severe allergic, and immune-mediated reactions have been observed in some patients during alglucosidase alfa infusions. Therefore, appropriate medical support measures should be readily available when alglucosidase alfa is administered.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of cardiorespiratory failure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <b>Lumizyme:</b> Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of cardiac or respiratory compromise due to fluid overload and require additional monitoring.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <b>Myozyme:</b> Patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to infusion reactions and require additional monitoring.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932456\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lumizyme;</li>\n      <li>Myozyme [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10304109\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Myozyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932460\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10457044\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pompe disease:</b> <i>Noninfantile, late-onset (Lumizyme):</i> IV: 20 mg/kg every 2 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932610\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=alglucosidase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alglucosidase alfa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pompe disease:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Infantile-onset (Lumizyme, Myozyme):</i> Infants &ge;1 month, Children, and Adolescents: 20 mg/kg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Noninfantile, late-onset (Lumizyme):</i> Infants &ge;1 month, Children, and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671396\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671397\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932616\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lumizyme: 50 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myozyme: 50 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932458\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932611\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse through a low-protein-binding, 0.2 micron in-line filter. Infuse over ~4 hours; initiate at 1 mg/kg/hour. If tolerated, increase by 2 mg/kg/hour every 30 minutes to a maximum rate of 7 mg/kg/hour. Decrease rate or temporarily hold for mild to moderate infusion reactions. Monitor vital signs prior to each rate increase. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932582\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pompe disease: </b>For use in patients with Pompe disease (acid alpha-glucosidase [GAA]  deficiency).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Limitations of use: Myozyme: Improves ventilator-free survival in patients with infantile-onset Pompe disease compared with an untreated historical control, whereas use of Myozyme in patients with other forms of Pompe disease has not been adequately studied to ensure safety and efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2933646\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alglucosidase alfa may be confused with agalsidase alfa, agalsidase beta, alglucerase</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932592\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Oxygen saturation decreased (infants and children 8% to 41%), tachycardia (infants and children 8% to 23%), bradycardia (infants and children 21%), flushing (5% to 21%), chest pain (17%), peripheral edema (3% to 17%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Pain (postprocedural; infants and children 26%; adults 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (infants and children 18% to 54%; adults &ge;3%), diaper rash (infants and children 36%), urticaria (8% to 21%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (infants and children 62%; adults &ge;3%), vomiting (infants and children 5% to 49%; adults 5% to 22%), gastroenteritis (infants and children 41%; adults 10%), oral candidiasis (infants and children 31%), gastroesophageal reflux disease (infants and children 26%), constipation (infants and children 23%; adults 10%), upper abdominal pain (children and adolescents 15%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (infants and children 31%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (infants and children 51%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Development of IgG antibodies (adults 100%; infants and children 89%; may affect efficacy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Catheter infection (infants and children 28%), infusion site reaction (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (37%), stiffness (15%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Otitis media (infants and children 33% to 44%), auditory impairment (33%), otalgia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (infants and children 8% to 46%), pneumonia (infants and children 46%), upper respiratory tract infection (infants and children 44%; adults 18%), pharyngitis (infants and children 36%; children and adolescents 9%), respiratory distress (infants and children 33%), respiratory failure (infants and children 31%), rhinorrhea (infants and children 28%), bronchiolitis (infants and children 23%), nasopharyngitis (infants and children 23%), tachypnea (infants and children 8% to 23%), respiratory syncytial virus infection (infants and children &gt;10%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (infants and children 15% to 92%), infusion related reaction (infants and children 51%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (infants and children 10%), chest discomfort (7%), increased blood pressure (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Pain (8%), vertigo (7%), malaise (5% to 6%), dizziness (&ge;5%), fatigue (&ge;5%), headache (&ge;5%), agitation (infants and children 5%), drowsiness (5%), rigors (infants and children 5%), paresthesia (&ge;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (10%), hyperhidrosis (8%), erythema (infants and children 5%), pallor (infants and children 5%), papular rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (8%), nausea (&ge;5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Lymphadenopathy (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Anaphylaxis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Local swelling (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle twitching (7% to 8%), tremor (5% to 7%), myalgia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Nephrolithiasis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (7%), rhinitis (children and adolescents 6%), cyanosis (&ge;5%), epistaxis (5%), respiratory tract infection (5%), pharyngeal edema (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acute cardiorespiratory failure, anaphylactic shock, angioedema (including tongue or lip swelling, periorbital edema, and face edema), aortic dissection, apnea, arthritis, back pain, bronchospasm, cardiac arrest, cardiac failure, cardiorespiratory arrest, cerebrovascular accident, cold extremities, conjunctivitis, convulsions, coronary artery disease, dehydration, dermal ulcer, diaphoresis, facial edema, flu-like symptoms, hemothorax, herniated disk, hyperparathyroidism, hypersensitivity, hypervolemia, hypotension, hypoxia, increased erythrocyte sedimentation rate, increased lacrimation, insomnia, irritability, livedo reticularis, muscle spasm, nephrotic syndrome (secondary to membranous glomerulonephritis), nervousness, nodal arrhythmia, periorbital edema, pneumothorax, proteinuria, pulmonary infection, rales, respiratory arrest, restlessness, retching, sepsis, skin necrosis, stridor, ventricular premature contractions, wheezing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932588\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932589\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; IgG antibody formation: The presence of IgG antibodies has been observed within 3 months from the onset of therapy in the majority of patients. High and sustained IgG antibody titers may result in reduced efficacy of alglucosidase alfa (eg, loss of motor function, ventilator dependence, death). Regularly monitor all patients for development of IgG antibodies; consider testing for IgG titers in patients who develop hypersensitivity reactions, other immune-mediated reactions, or loss of clinical response. Patients with reduced clinical response may also be tested for inhibitory antibody activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[U.S. Boxed Warning]: Life-threatening anaphylactic reactions and severe hypersensitivity reactions, some of which were IgE mediated, may occur; immediate medical support should be readily available.</b>   Reactions may occur during and up to 3 hours after infusion. Patients who develop IgE antibodies to alglucosidase alfa may be at a higher risk; monitor these patients closely during administration. Consider testing for IgG titers in patients who develop allergic reactions; may also test for IgE antibodies or other mediators of anaphylaxis. Consider risks/benefits of readministration following an anaphylactic or severe allergic reaction; some patients have been rechallenged under close clinical supervision; appropriate resuscitation measures should be available. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immune-mediated adverse effects: <b>[U.S. Boxed Warning]: Severe immune-mediated reactions (eg, necrotizing skin lesions, nephrotic syndrome secondary to membranous glomerulonephritis, proteinuria, inflammatory arthropathy) may occur; immediate medical support should be readily available.</b> Reactions have occurred up to 3 years after initiation of therapy. Monitor urinalysis periodically. Monitor for immune-mediated reaction development. Consider testing for IgG titers in patients who develop immune-mediated reactions; may also test for IgE antibodies. Consider risks/benefits of readministration; some patients have been successfully rechallenged under close clinical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reactions: Infusion-related reactions are common and may occur during and up to 2 hours after infusion. Appropriate medical support for the management of infusion reactions should be readily available. Discontinue immediately for severe hypersensitivity or anaphylactic reaction; mild to moderate reactions may be managed by reducing the infusion rate and/or administering antihistamines and/or antipyretics. Use caution with subsequent infusions; infusion reactions have occurred despite premedication with antihistamines, antipyretics, and/or corticosteroids. Patients with acute underlying illness are at greater risk for infusion reactions, including cardiorespiratory failure; monitor closely during infusion. Although less common, delayed-onset (within 48 hours after administration) infusion reactions have also occurred. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: <b>[U.S. Boxed Warning]: Use with caution in patients with compromised cardiac function; risk of acute cardiorespiratory failure secondary to infusion-related reactions or fluid overload may be increased. Additional monitoring is warranted.</b> Cardiorespiratory failure has been observed in patients with cardiac hypertrophy up to 72 hours after infusion; arrhythmias have also been observed in patients with cardiac hypertrophy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: <b>[U.S. Boxed Warning]: Use with caution in patients with compromised respiratory function; risk of acute cardiorespiratory failure secondary to infusion-related reactions or fluid overload may be increased. Additional monitoring is warranted.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sepsis: Patients with sepsis may be at increased risk for cardiorespiratory failure during infusions. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anesthesia: Use of general anesthesia for catheter placement for alglucosidase alfa infusions may be complicated by the presence of cardiac and skeletal (including respiratory) muscle weakness in patients with Pompe disease; use general anesthesia with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Registry: A registry has been created to monitor therapeutic responses and adverse effects during long-term treatment; patients should be encouraged to register (www.pomperegistry.com or 1-800-745-4447).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298706\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6217680\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9280&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932583\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932584\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in some animal reproduction studies. Use of alfa-glucosidase in pregnant women has been reported (Perniconi 2016; Rohman 2016; Santos 2016; Zagnoli 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A registry has been established for Pompe patients; women of childbearing potential are encouraged to enroll in the registry (www.pomperegistry.com or 1-800-745-4447).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932587\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Endogenous acid alfa-glucosidase can be detected in breast milk; concentrations are lower in women with Pompe disease. Following an infusion of alglucosidase alfa in one woman with Pompe disease, maximum enzyme activity was found in breast milk 2.5 hours after the dose and was ~0.3% of the maternal peak plasma value. Activity in breast milk returned to baseline values within 24 hours after the infusion (de Vries, 2011). The manufacturer recommends that caution be used if administered to breast-feeding women; exposure may be minimized by temporarily pumping and discarding breast milk for 24 hours after administration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">A registry has been established for Pompe patients; women who are breast-feeding are encouraged to enroll in the registry (www.pomperegistry.com or 1-800-745-4447)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932613\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Liver enzymes (baseline and periodically; elevation may be due to disease process); vital signs (prior to each infusion rate increase) during and following infusion; immune-mediated reactions; volume overload; urinalysis (periodically) </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommends monitoring for IgG antibody formation every 3 months for 2 years, then annually. Consider testing if patient develops allergic or other suspected immune-mediated reaction or experiences loss of clinical response. No commercial tests are available; however, sampling kits can be obtained by contacting Genzyme Corporation at 1-800-745-4447. Patients who experience anaphylactic or allergic reactions may also be tested for IgE antibodies to alglucosidase alfa and other mediators of anaphylaxis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932603\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Alglucosidase alfa is a recombinant form of the enzyme acid alpha-glucosidase (GAA), which is required for glycogen cleavage. Due to an inherited GAA deficiency or absence, glycogen accumulates in the tissues of patients with Pompe disease, leading to progressive muscle weakness. In infantile-onset Pompe disease, glycogen accumulates in cardiac and skeletal muscles and hepatic tissue, leading to cardiomyopathy and respiratory failure. Juvenile- and adult-onset Pompe disease are limited to glycogen accumulation in skeletal muscle, leading to respiratory failure. Alglucosidase alfa binds to mannose-6-phosphate receptors on the cell surface, is internalized, and transported to lysosomes where it is activated for increased enzymatic glycogen cleavage. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932605\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>ss</sub>: Infants 1 to 7 months: 96 &plusmn; 16 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Infants 1 to 7 months: 2.3 hours; Adults: 2.4 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322941\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Lumizyme Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $922.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539973\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Myozyme (AT, AU, BE, BG, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IT, JP, KR, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PL, PT, RO, RU, SE, SG, SI, SK, SV, TH, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amalfitano A, Bengur AR, and Morse RP, &ldquo;Recombinant Human Acid Alpha-Glucosidase Enzyme Therapy for Infantile Glycogen Disease Type II: Results of a Phase I/II Clinical Trial,&rdquo; <i>Genet Med</i>, 2001, 3(2):132-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/11286229/pubmed\" target=\"_blank\" id=\"11286229\">11286229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Vries JM, Brugma JD, Ozkan L, et al, &quot;First Experience With Enzyme Replacement Therapy During Pregnancy and Lactation in Pompe Disease,&quot; <i>Mol Genet Metab</i>, 2011, 104(4):552-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/21967859/pubmed\" target=\"_blank\" id=\"21967859\">21967859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klinge L, Straub V, Neudorf U, et al, &ldquo;Enzyme Replacement Therapy in Classical Infantile Pompe Disease: Results of a Ten-Month Follow-up Study,&rdquo; <i>Neuropediatrics</i>, 2005, 36(1):6-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/15776317/pubmed\" target=\"_blank\" id=\"15776317\">15776317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klinge L, Straub V, Neudorf U, et al, &ldquo;Safety and Efficacy of Recombinant Acid Alpha-Glucosidase (rhGAA) in Patients With Classical Infantile Pompe Disease: Results of a Phase II Clinical Trial,&rdquo; <i>Neuromuscular Disorders</i>, 2005, 15(1):24-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/15639117/pubmed\" target=\"_blank\" id=\"15639117\">15639117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lumizyme (alglucosidase alfa) [prescribing information]. Cambridge, MA: Genzyme Corp; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myozyme (alglucosidase alfa) [prescribing information]. Cambridge, MA: Genzyme Corp; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perniconi B, Vauthier-Brouzes D, Mor&eacute;lot-Panzini C, et al. Multidisciplinary care allowing uneventful vaginal delivery in a woman with Pompe disease. <i>Neuromuscul Disord</i>. 2016;26(9):610-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/27460347/pubmed\" target=\"_blank\" id=\"27460347\">27460347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rohman PJ, Scott E, Richfield L, Ramaswami U, Hughes DA. Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease). <i>J Obstet Gynaecol Res</i>. 2016;42(10):1263-1271.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/27384519/pubmed\" target=\"_blank\" id=\"27384519\">27384519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos M, Conceicao I. Enzyme replacement therapy with alglucosidase alpha and pregnancy in late-onset Pompe disease [abstract]. <i>Eur J Neurol</i>. 2016;23:688.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Ploeg AT, Clemens PR, Corzo D, et al, &ldquo;A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe&rsquo;s Disease, <i>N Engl J Med</i>, 2010, 362(15):1396-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/20393176/pubmed\" target=\"_blank\" id=\"20393176\">20393176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zagnoli F, Leblanc A, Blanchard C. Pregnancy during enzyme replacement therapyfor late-onset acid maltase deficiency. <i>Neuromuscul Disord</i>. 2013;23(2):180-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alglucosidase-alfa-drug-information/abstract-text/23290485/pubmed\" target=\"_blank\" id=\"23290485\">23290485</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9280 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708603\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2932456\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10304109\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2932460\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F10457044\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2932610\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671396\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671397\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2932616\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2932458\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2932611\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2932582\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2933646\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2932592\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2932588\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2932589\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298706\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6217680\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2932583\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2932584\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2932587\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2932613\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2932603\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2932605\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322941\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539973\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9280|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alglucosidase-alfa-patient-drug-information\" class=\"drug drug_patient\">Alglucosidase alfa: Patient drug information</a></li><li><a href=\"topic.htm?path=alglucosidase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">Alglucosidase alfa: Pediatric drug information</a></li></ul></div></div>","javascript":null}